$-0.51 EPS Expected for Quotient Limited (QTNT)

May 16, 2018 - By Marguerite Chambers

Quotient Limited (NASDAQ:QTNT) LogoInvestors sentiment increased to 1.93 in 2017 Q4. Its up 0.51, from 1.42 in 2017Q3. It improved, as 5 investors sold Quotient Limited shares while 10 reduced holdings. 7 funds opened positions while 22 raised stakes. 30.23 million shares or 41.49% more from 21.37 million shares in 2017Q3 were reported.
National Bank & Trust Of America Corp De holds 3,739 shares. Macquarie Gru Ltd accumulated 6,000 shares or 0% of the stock. Ny State Common Retirement Fund reported 13,700 shares or 0% of all its holdings. Rhumbline Advisers holds 0% of its portfolio in Quotient Limited (NASDAQ:QTNT) for 22,960 shares. The New York-based Lombard Odier Asset Mgmt (Usa) Corp has invested 0.06% in Quotient Limited (NASDAQ:QTNT). Parametric Port Associate Limited Liability reported 10,194 shares stake. Hudson Bay Limited Partnership stated it has 480,000 shares. State Street Corporation holds 0% or 378,984 shares. 6.80M were reported by Polar Cap Llp. Manufacturers Life Insurance Communications The owns 0% invested in Quotient Limited (NASDAQ:QTNT) for 4,939 shares. Millennium Mgmt Limited Co accumulated 0% or 503,735 shares. Sio Management Llc accumulated 1.43 million shares. Jpmorgan Chase And Company reported 0% of its portfolio in Quotient Limited (NASDAQ:QTNT). Wells Fargo Mn accumulated 33,961 shares. Bnp Paribas Arbitrage holds 0% in Quotient Limited (NASDAQ:QTNT) or 5,591 shares.

Since February 21, 2018, it had 1 buy, and 0 selling transactions for $51,348 activity.

Analysts expect Quotient Limited (NASDAQ:QTNT) to report $-0.51 EPS on May, 28.They anticipate $0.18 EPS change or 26.09 % from last quarter’s $-0.69 EPS. After having $-0.47 EPS previously, Quotient Limited’s analysts see 8.51 % EPS growth. The stock decreased 0.85% or $0.04 during the last trading session, reaching $4.65. About 190,152 shares traded. Quotient Limited (NASDAQ:QTNT) has declined 24.44% since May 17, 2017 and is downtrending. It has underperformed by 35.99% the S&P500.

Quotient Limited, a commercial-stage diagnostics company, develops, makes, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company has market cap of $211.99 million. The firm is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. It currently has negative earnings. It also develops, makes, and commercializes conventional reagent products for blood grouping, including antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping.

More news for Quotient Limited (NASDAQ:QTNT) were recently published by: Streetinsider.com, which released: “Quotient (QTNT) Announces FDA Approval of Seven Blood Bank Reagents, Including Two Market Firsts” on April 24, 2018. Globenewswire.com‘s article titled: “Quotient Limited to Report Fourth Quarter and Fiscal Full Year 2018 Financial Results and Host Conference Call” and published on May 15, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.